3DMedLIVE 2019: highlights from day two

6 Oct 2020

Written by Freya Leask, Kenny Dalgarno

Freya Leask (Future Science Group, London, UK) and Kenny Dalgarno (Newcastle University, UK) discuss their highlights from day two of 3DMedLIVE 2019: 3D printing in surgery and reflect on the key messages from the overall conference.

Biographies

For the past decade, Kenny Dalgarno has been conducting research in the area of additive manufacturing, with applications in rapid prototyping and manufacturing as well as polymer engineering. Dalgarno’s research has had an increasing emphasis on applications in biomedical engineering, tissue engineering and regenerative medicine with work supported by the Engineering and Physical Sciences Research Council (EPSRC), the European Commission, Arthritis Research UK, the Carbon Trust and industrial partners. Dalgarno currently maintains the position of Sir James Woodeson Professor of Manufacturing Engineering at Newcastle University, whilst simultaneously acting as Deputy Director of the Arthritis Research UK Tissue Engineering Centre, Deputy Director of the EPSRC’s Centre for Innovative Manufacturing in Medical Devices and as a Coordinator of the FP7 RESTORATION project. Dalgarno is also the Newcastle University Lead Investigator for the EPSRC Centre for Doctoral Training in Additive Manufacture and 3D Printing.

Freya Leask is a Publisher at Future Science Group. She was previously Editor of 3DMedNet and of RegMedNet, and launched The Evidence Base® in 2019. Prior to that, she held editorial and project management roles in the UK and Canada. Freya has worked in science communication and publishing for 5 years covering topics such as regenerative medicine, 3D printing in surgery, pharmaceutical development and basic life science research. She has an MChem in Chemistry from the University of Bradford.

“I think as we develop, it’s still integrating, in fact, and we’re making it seamless as we get there. 3D printing on its own doesn’t do things. Bioprinting on its own doesn’t do things. It’s integrating that, so that we have a kind of a solution. It is the big thing, I think, and then using that defined process to gather the evidence, validate and make sure we can show that there’s commercial value in it all.”

Dalgarno and Leask were interviewed at 3DMedLIVE 2019: 3D printing in surgery. To access more exclusive interviews and content from 3DMedLIVE 2019, watch this space on 3DMedNet >>

>> Find out more about 3DMedLIVE